TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: migration of implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Differences in the process of care between female and male patients
Endpoint domain: Delivery of care
Primary endpoint: number of patients with pain
Endpoint domain: Adverse events/effects
Primary endpoint: number of patients with self-limiting hematuria
Endpoint domain: Adverse events/effects
Primary endpoint: CO2 retention degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SpO2 from 100% to 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: NGB expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability in therapeutic dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients who were responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cecum intubation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine efficacy against AAP-defined AOM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma TMAO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: REE reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HOMA-beta reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: average number of workouts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative priming suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-reported change in water intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in body mass index z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five-year recurrence-free survival (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: Patient-reported improvement after treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physician evaluation of improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vaginal pH measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall satisfaction with posthospital care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Induction of CD8+ CTL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Development of neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: problems with waking up at night
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: MMSE improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MoCA improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG complexity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Symptom severity (ICIQ-UI SF score reduction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Condition-specific quality of life (ICIQ-LUTSqol score reduction)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Direct cost of VMMC procedure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Heart rate recovery (HRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of complete response (no PONV and no need for rescue antiemetic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Developmental normalcy after one year
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Acceptability of the service model
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients achieving >2 grades improvement in CFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30% improvement in symptoms (Ocular Surface Disease Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean adjusted CFS change from baseline to month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence and levels of A actinomycetemcomitans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cancer diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total bifidobacteria increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Exogenous bifidobacteria increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Beta-glucuronidase activity decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in pediatric intensive care resource use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of individuals not requiring medications for T2DM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reductions in percent body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCP perceived effectiveness in treating behavioral problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in managing oppositional/aggressive behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PCP‐perceived improvement in managing attention-deficit hyperactivity disorder
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: POEM score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacologic VMA resolution at day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥2‐line improvement in BCVA from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nonsurgical FTMH closure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of serious infections (SIEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma tHcy levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum amyloid A (S‐AA) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma intercellular adhesion molecule‐1 (ICAM‐1) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in rapid mood shifts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse neurological outcome
Endpoint domain: Adverse events/effects
Primary endpoint: relative death rate
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of postoperative seroma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade ⩾2 rash
Endpoint domain: Adverse events/effects
Primary endpoint: Indexes of blood gas analysis (pH, PO2, PaCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Left atrial fractional shortening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total atrial fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: End-diastolic mitral flow velocity amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: three-year disease-free survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: incidence of severe side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Early post-operative physical disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early post-operative residual leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of endoscopic intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in novel oral anticoagulant (NOAC) initiations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in prescribers' choice between different NOACs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cognitive performance as measured by MDRS I/P
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive performance as measured by MMSE
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: area under the concentration‐time curve (AUC0‐t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the concentration‐time curve (AUC0‐infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pore size of PLA scaffolds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIQR-function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 5TSTS performance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PVR improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nosocomial infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mental Development Index <70
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral palsy diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurodevelopmental impairment incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Extraction ratio for contrast media
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean extracorporeal plasma clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical stage T3 vs. cT1-2
Endpoint domain: Mortality/survival
Primary endpoint: Serum albumin <4.0 g/dl vs. > 4.0 g/dl
Endpoint domain: Mortality/survival
Primary endpoint: Pathological curability B vs. pA
Endpoint domain: Mortality/survival
Primary endpoint: Initial need for surgical reintervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Extent of bowel contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: net absorption of proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: net absorption of lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: net absorption of energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean serum IGF-I concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean P300 latencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: exercise test duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: emergence of antibiotic resistance
Endpoint domain: Adverse events/effects
Primary endpoint: length of ICU stay
Endpoint domain: Resource use
Primary endpoint: risk of short-term clinically important deterioration
Endpoint domain: Adverse events/effects
Primary endpoint: sleep-onset latency ≤ 30 minutes
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Mean 24 h urine protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: perceived short term benefits from mental practice
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: quality-adjusted life-year gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean reduction in pain diary score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: less procedure-related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients obtaining >50% pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: impulsive decision-making
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean blood flow through the brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: plasma Hcy levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urinary EDN levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nerve fibre layer haemorrhages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Strength of effects reported after alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to spontaneous ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cost-effectiveness of Cognitive Self-Therapy (CST)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: SCL-90 results
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 12-week responder rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cognitive improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: athletic strength and performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: comfort level of mouthguards
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: difficulty in breathing
Endpoint domain: Adverse events/effects
Primary endpoint: Latency to Persistent Sleep (LPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean spherical equivalent refractive error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma ANF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma osmolality levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AVP threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global sexual function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: orgasm function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TSH elevation over 5.0 mIU/liter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: TSH suppression below 0.5 mIU/liter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Attention‐Deficit/Hyperactivity Disorder Rating Scale IV total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADASc score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lowering perceived uncertainty and anxiousness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: enhancing the locus of control during birth
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improve the rate of 3cm-or-greater cervical dilation at admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of repeated procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean hospital days from bowel preparation initiation to discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Subjective craving ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cue-induced brain activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progressive visual field deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term intraocular pressure fluctuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum creatinine increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: biochemical markers of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient satisfaction with feedback intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive relationships with other residents
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Stronger alliance with treatment program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Voiding function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Male sexual function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Eating Disorder Inventory 2 Drive for Thinness subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating Disorder Inventory 2 Interpersonal Distrust subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of hot flashes per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean severity of hot flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nNO measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory biomarkers concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visual analog scale score (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: VAT cross‐sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma insulin area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: POGO scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total symptom score for days 1-4 following chilling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of cold symptoms in subjects who were chilled
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of CLABSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ocular surface effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anesthetic agent requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent change of hs-CRP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SKAMP-Combined score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in brachial artery diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in FMD (Flow-Mediated Dilation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in AIx (Augmentation Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in cognition assessed by ADAS-Cog
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in behavior and mood assessed by ADAS-non-Cog
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in activities of daily living (ADL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteriologic treatment success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sensitivity for detecting coronary artery disease (≥ 50% stenosis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of direction performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Star Excursion performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single-leg stability evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: discomfort rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: range of joint movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: usability rating
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean HAM-D score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diuresis (urine output)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rescreening rates within 28 days of enrollment
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Complete occlusion of femoral veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of spontaneous movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes